Perpinia Anastasia Stella, Kadoglou Nikolaos, Vardaka Maria, Gkortzolidis Georgios, Karavidas Apostolos, Marinakis Theodoros, Papachrysostomou Chrysostomi, Makaronis Panagiotis, Vlachou Charikleia, Mantzourani Marina, Farmakis Dimitrios, Konstantopoulos Konstantinos
Department of Cardiology, "G. Gennimatas" General Hospital, 11527 Athens, Greece.
Medical School, University of Cyprus, Nicosia 2029, Cyprus.
Pharmaceuticals (Basel). 2022 Aug 16;15(8):1007. doi: 10.3390/ph15081007.
Modern treatment modalities in hematology have improved clinical outcomes of patients with hematological malignancies. Nevertheless, many new or conventional anticancer drugs affect the cardiovascular system, resulting in various cardiac disorders, including left ventricular dysfunction, heart failure, arterial hypertension, myocardial ischemia, cardiac rhythm disturbances, and QTc prolongation on electrocardiograms. As these complications may jeopardize the significantly improved outcome of modern anticancer therapies, it is crucial to become familiar with all aspects of cardiotoxicity and provide appropriate care promptly to these patients. In addition, established and new drugs contribute to primary and secondary cardiovascular diseases prevention. This review focuses on the clinical manifestations, preventive strategies, and pharmaceutical management of cardiotoxicity in patients with hematologic malignancies undergoing anticancer drug therapy or hematopoietic stem cell transplantation.
血液学中的现代治疗方法已改善了血液系统恶性肿瘤患者的临床结局。然而，许多新型或传统抗癌药物会影响心血管系统，导致各种心脏疾病，包括左心室功能障碍、心力衰竭、动脉高血压、心肌缺血、心律紊乱以及心电图QTc延长。由于这些并发症可能会危及现代抗癌治疗显著改善的结局，因此熟悉心脏毒性的各个方面并及时为这些患者提供适当护理至关重要。此外，已有的和新型药物有助于原发性和继发性心血管疾病的预防。本综述重点关注接受抗癌药物治疗或造血干细胞移植的血液系统恶性肿瘤患者心脏毒性的临床表现、预防策略和药物管理。
